INDIVIOR PLC/S (OTCMKTS:INVVY) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Friday.
According to Zacks, “Indivior PLC operates as a specialty pharmaceutical company. It is engaged in discovering and developing medications and treatment for alcohol addiction, opioid overdose, cocaine intoxication and co-occurring conditions, such as schizophrenia. The Company markets and promotes SUBOXONE (buprenorphine and naloxone) Sublingual Film, SUBOXONE (buprenorphine and naloxone) Sublingual Tablet, and SUBUTEX (buprenorphine) Sublingual Tablet, each buprenorphine-based treatment for opioid. Indivior PLC is based in United States. “
Separately, ValuEngine upgraded shares of INDIVIOR PLC/S from a “sell” rating to a “hold” rating in a research report on Tuesday, July 17th.
Shares of INDIVIOR PLC/S stock opened at $13.15 on Friday. INDIVIOR PLC/S has a twelve month low of $11.54 and a twelve month high of $33.83. The stock has a market cap of $1.92 billion, a PE ratio of 7.31 and a beta of 0.69.
INDIVIOR PLC/S (OTCMKTS:INVVY) last issued its earnings results on Thursday, November 1st. The company reported $0.40 earnings per share for the quarter. The business had revenue of $245.00 million for the quarter. Analysts anticipate that INDIVIOR PLC/S will post 1005 earnings per share for the current year.
About INDIVIOR PLC/S
Indivior PLC is a holding company, which engages in the manufacture and distribution of buprenorphine-based prescription drugs for treatment of opioid dependence. Its products include Suboxone Film, Suboxone Tablet, Subutex Tablet, and Sublocade Injection. The company was founded on September 26, 2014 and is headquartered in Slough, the United Kingdom.
Featured Story: What are the Benefits of Index Funds?
Get a free copy of the Zacks research report on INDIVIOR PLC/S (INVVY)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for INDIVIOR PLC/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INDIVIOR PLC/S and related companies with MarketBeat.com's FREE daily email newsletter.